Company:  GERON CORP (GERN)
Form Type:  SC 13G/A
Filing Date:  2/17/1998 
CIK:  0000886744 
Address:  149 COMMONWEALTH DRIVE
SUITE 2070
 
City, State, Zip:  MENLO PARK, California 94025 
Telephone:  (650) 473-7700 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.48  
Change: 
0.00 (0.00%)  
Trade Time: 
Nov 11  
Market Cap: 
$295.67M
Trade GERN now with 

© 2019  
Description of Business
We are a late-stage clinical biopharmaceutical company that is focused on the development and commercialization of innovative therapeutics for hematologic myeloid malignancies. We have global rights to imetelstat, a first-in-class telomerase inhibitor, that was discovered and developed at Geron. We believe clinical data from two Phase 2 clinical trials of imetelstat (IMerge and IMbark, discussed below) conducted by Janssen Biotech, Inc., or Janssen, support further development of imetelstat in hematologic myeloid malignancies. We are working with Janssen to transition the imetelstat program to us. See further discussion below regarding our past and current relationship with Janssen.
Register and access this filing in:     
  FORM SC 13G/A